Acasti Pharma Inc. (ACST)
NASDAQ: ACST · Real-Time Price · USD
3.270
-0.080 (-2.39%)
Oct 14, 2024, 4:00 PM EDT - Market closed
Company Description
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage.
It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.
The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Acasti Pharma Inc.
| Country | United States |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Prashant Kohli |
Contact Details
Address: 103 Carnegie Center, Suite 300 Princeton, New Jersey 08540 United States | |
| Phone | 818-839-4378 |
| Website | acastipharma.com |
Stock Details
| Ticker Symbol | ACST |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001444192 |
| CUSIP Number | 00430K402 |
| ISIN Number | CA00430K8656 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Prashant Kohli | Chief Executive Officer and Director |
| Amresh Kumar Ph.D. | Vice President of Program Management |
| Carrie D'Andrea | Vice President of Clinical Operations |
| Robert J. DelAversano CPA | Vice President of Finance and Principal Financial and Accounting Officer |
| Dr. R. Loch MacDonald M.D., Ph.D. | Member of Scientific Advisory Board and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 8, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Oct 8, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 8, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 8, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 8, 2024 | POS AM | Post-Effective amendments for registration statement |
| Oct 8, 2024 | POS AM | Post-Effective amendments for registration statement |
| Oct 7, 2024 | 8-K | Current Report |
| Sep 30, 2024 | 8-K | Current Report |
| Sep 25, 2024 | 8-K | Current Report |
| Sep 6, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |